Oxford COVID-19 vaccine doing 'everything expected'; says study calling it 'good news'

Oxford University COVID-19 vaccine, which is currently undergoing Phase III, clinical trial with Pharma Giant AstraZeneca is doing “everything expected”, an independent analysis stated on October 22. analysis, which was conducted by researchers from Bristol University, examined vaccine candidates ChOx1 and also AZD1222, to see “what it does when it gets inside a human cell.”

For purpose, y developed techniques to validate vaccine accurately following genetic instructions programmed into it by Oxford University team. Writing in paper published in Preprint server ResearchSquare, y explained that latest analysis gives an insight into how vaccine provokes a strong immune response.

Re: AstraZeneca Gets Approval Recommendation For Two Drugs From EU ncy

"This is an important study as we are able to confirm that genetic instructions underpinning this vaccine, which is being developed as fast as safely possible, are correctly followed when y get into a human cell," said Dr David Matws, Reer in Virology from Bristol's School of Cellular and Molecular Medicine (CMM), who led research.

He furr ded that although techlogy hasn’t been able to “provide answers with clarity” until w, it h definitely me sure that vaccine was “doing everything expected." "And that is only good news in our fight against illness," he said.

Re: COVID-19: AstraZeneca Begins Late-st Trials Of Vaccine With 6,000 Participants

Work on vaccine candidate developed by University of Oxford's Jenner Institute and Oxford Vaccine Group, began in January this year. Earlier this week, Brazilian health authority Anvisa said that a volunteer in  clinical trial of COVID-19 vaccine h died. company stated that it h received data from an investigation into matter and ded that  testing of vaccine would continue after volunteer's death. 

Functioning of AZD1222

COVID-19 vaccine candidate, AZD1222, developed by Oxford University and AstraZeneca start producing coronavirus spike protein after it enters cells. spike protein prompts immune system to produce antibodies and trigger T-cells to destroy infected cells. If individual encounters vel coronavirus, antibodies and T-cells are activated to fight virus.

Re: COVID-19: AstraZeneca Vaccine Trial Volunteer Dies, Authorities Say Testing To Continue

Re: Thailand Agrees To Manufacture, Supply AstraZeneca's Experimental COVID-19 Vaccine

Im: AP